These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 12373528)

  • 21. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
    Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-related motor complications--phenomenology.
    Fox SH; Lang AE
    Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.